drugset

drugset / Trial / NCT00325689

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689 ↗

Phase 4 Completed 323 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.

Timeline

Start: 2006-07
Primary completion: 2007-10
Completion: 2007-10

Publications

Background Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assuncao-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aripiprazole	Other / unclassified	2 mg	Oral
Comparator	Aripiprazole	Other / unclassified	15 mg	Oral
Comparator	Quetiapine	Small molecule	400 mg	Oral
Comparator	Quetiapine	Small molecule	800 mg	Oral
Comparator	Risperidone	Other / unclassified	4 mg	Oral
Comparator	Risperidone	Other / unclassified	8 mg	Oral

Indications